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Abstract: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting 
motor neurons in the brain, brainstem and spinal cord, which is characterized by motor 
dysfunction, muscle dystrophy and progressive paralysis. Both inherited and sporadic 
forms of ALS share common pathological features, however, the initial trigger of 
neurodegeneration remains unknown. Motor neurons are uniquely targeted by ubiquitously 
expressed proteins in ALS but the reason for this selectively vulnerability is unclear. 
However motor neurons have unique characteristics such as very long axons, large cell 
bodies and high energetic metabolism, therefore placing high demands on cellular transport 
processes. Defects in cellular trafficking are now widely reported in ALS, including 
dysfunction to the molecular motors dynein and kinesin. Abnormalities to dynein in 
particular are linked to ALS, and defects in dynein-mediated axonal transport processes 
have been reported as one of the earliest pathologies in transgenic SOD1 mice. 
Furthermore, dynein is very highly expressed in neurons and neurons are particularly 
sensitive to dynein dysfunction. Hence, unravelling cellular transport processes mediated 
by molecular motor proteins may help shed light on motor neuron loss in ALS. 
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Amyotrophic lateral sclerosis (ALS), also known as Charcot’s sclerosis or Lou Gehrig’s disease, is 
the most common form of motor neuron disease. It is characterized by progressive degeneration of 
motor neurons in the primary cortex, brainstem, and spinal cord, which results in muscle dystrophy, 
paralysis, and death. The fatal event is usually failure of the respiratory muscles. At least 10% of all 
ALS cases are inherited (familial ALS); however, most cases have no discernable genetic component 
(sporadic ALS). Several proteins are linked to sporadic and familial forms of ALS, notably superoxide 
dismutase 1 (SOD1) [1], TAR DNA binding protein 43 (TDP-43) [2], and fused in sarcoma (FUS) [3]. 
Both sporadic and familial forms of ALS are clinically and pathologically identical.  
Of the cases of familial ALS, approximately 20% are linked to dominantly inherited mutations in 
SOD1. Mutant SOD1 has been extensively studied in both cellular and animal models of disease. As a 
multifactorial disorder, several mechanisms have been implicated in the neurodegenerative process in 
ALS. These include protein misfolding and aggregation, excitotoxicity [4], neuro-inflammation [5,6], 
endoplasmic reticulum (ER) stress, oxidative stress [7] and mitochondrial dysfunction [8], cytoskeleton 
abnormalities and defective axonal transport [9,10]. However, the initiating factors which trigger 
neurodegeneration still remain unknown. Recently, increasing evidence implicates dysfunction of the 
cellular transport machinery in ALS, including dysfunction to the molecular motor proteins, dynein 
and kinesin.  
A perplexing characteristic of ALS is why motor neurons are targeted by ubiquitously expressed 
proteins. Motor neurons are large, highly differentiated, polarized cells, with extremely long axons, up 
to 1 metre in length in an adult human. Hence, they have high synthetic and energy requirements, 
which therefore places heavy demands on cellular transport processes [11]. Proteins, lipids, mRNA 
and organelles need to rapidly move from the cell body over large distances along the axon to the 
synaptic terminals or neuromuscular junctions, where they are required for axoplasmic membrane 
remodeling, energy production, neurotransmission and local protein synthesis [12]. Axonal transport is 
also required to collect neurotrophins, survival factors or potentially toxic factors from distal axons, 
peripheral synapses or muscle cells, back to the soma. The complexity and fine regulation of this 
system is highly sensitive to perturbation, and minor alterations of cellular and vesicular transport 
processes may result in motor neuron dysfunction [13].  
Axonal transport is a key mechanism required for cellular viability in neuronal cells. Most proteins 
required in the axon and in synaptic terminals must be transported along the axon after synthesis in the 
cell body. Similarly RNA and organelles also need to be transported over long distances, and these 
transport processes require molecular motors, such as kinesins, dyneins and myosins, that operate 
along the cellular cytoskeleton. Dysfunction of axonal transport has been described in several 
neurodegenerative diseases, and is well documented in ALS [9,14,15]. In this review, we describe the 
functions of the molecular motors, including kinesins and dyneins, as well as their putative roles   
in ALS.  Int. J. Mol. Sci. 2011, 12 9059 
 
 
2. Genetics of ALS 
Although most cases of ALS are sporadic, approximately 10% of all cases are inherited, and 
investigations into the genetic causes of ALS may prove to be important for uncovering common 
disease mechanisms [16,17]. Mutations in SOD1 were the first identified and remain the best 
characterized dominantly inherited causative genetic mutations in ALS [1]. However, in recent years 
additional genes have been linked with disease and most of these have arisen from studies of small 
familial pedigrees with dominantly-inherited ALS. However, mutations have also been identified in 
subsets of sporadic ALS cases, indicating that de novo mutations can cause disease, and suggesting 
that genetic changes are important in both familial and sporadic ALS. 
Mutations in SOD1 are scattered amongst all five exons of the SOD1 gene. SOD1 is a cytoplasmic 
protein, and mutant SOD1 proteins are prone to aggregation and intracellular inclusion formation. The 
most widely used and well-characterized experimental model of human ALS is the SOD1
G93A 
transgenic mice, which develops progressive muscular weakness and paralysis similar to human   
ALS [18]. Structural abnormalities of motor neurons are evident in SOD1
G93A transgenic mice, such  
as dilated ER in axons, dendrites, and cell bodies, as well as vacuoles associated with swollen 
degenerating mitochondria [19].  
The second most common gene linked to ALS after SOD1 is fused in sarcoma (FUS) [3,20] and 
FUS mutations are found in up to 5% of familial ALS patients [3,20]. Mutations in FUS are found in 
both familial and sporadic ALS, as well as in patients with ALS and frontotemporal dementia (FTD), 
and in frontotemporal lobar degeneration (FTLD) patients without motor impairment [3,20–23], 
suggesting a pathogenic overlap between ALS and other neurodegenerative diseases. Most identified 
mutations cluster in the C-terminal portion of the protein, around the nuclear localization sequence. 
TDP-43 is the major constituent of cytoplasmic and intracellular inclusions in neurons and glia of 
patients with sporadic and familial ALS [2,24]. More than 30 different mutations in the gene encoding 
TDP-43, TARDBP, have now been reported in 3 to 4% of cases of familial ALS [25,26]. The functions 
of both FUS and TDP-43 are largely uncharacterized, although the structural and functional similarities 
between these two proteins suggest that similar disease mechanisms could operate for both proteins. 
Transgenic mice overexpressing either wildtype or mutant TDP-43 produces similar phenotypes [27]. 
However, the mechanisms causing pathogenesis in the mutant TDP-43 transgenic mice remain 
unknown, although abnormal cytoplasmic mitochondrial aggregates and early lethality have been 
identified [27]. 
Several forms of juvenile-onset ALS have been characterized, such as ALS2, with a very slow 
disease progression. Mutations in ALS2, which are autosomal recessive, are thought to involve vesicle 
transport and membrane trafficking processes [28]. Another juvenile-onset ALS is autosomal dominant 
ALS4 linked to mutations in the SETX gene encoding senataxin, which is thought to   
possess DNA/RNA helicase acitivty [29]. A single mutation, P56S, in vesicle associated membrane 
protein/synaptobrevin-associated  membrane protein B (VAPB) are also described in a form of 
autosomal-dominant late-onset ALS (ALS8) [30]. Mutations in tau and the p150 dynactin subunit are 
also described in ALS-dementia and lower ALS respectively, and cause progressive, autosomal 
dominant forms of diseases and without sensory symptoms [31,32]. In 2010, two further ALS-
causative genes, optineurin [33] and valosin containing protein (VCP) [34], were identified. Mutations Int. J. Mol. Sci. 2011, 12 9060 
 
 
in optineurin are found in both sporadic and SOD1-linked ALS [33,35]; but VCP mutations have only 
been identified in familial ALS cases [34]. Mutations in the gene encoding ubiquitin-like protein 
ubiquilin 2, UBQLN2, which cause dominantly inherited, were also recently linked to chromosome-X-
linked ALS and ALS/dementia [36]. Ubiquilin 2 is a member of the ubiquilin family, which regulates 
the degradation of ubiquitinated proteins [36], and mutations in UBQLN2 lead to an impairment of 
protein degradation [36]. A more recent report identifies a noncoding expanded GGGGCC 
hexanucleotide repeat in C9ORF72 as the cause of chromosome 9p-linked FTD/ALS and shows that 
this genetic defect is the most common cause of ALS and FTD identified to date [37]. 
3. Possible Pathogenic Mechanisms in ALS 
Despite the fact that a number of genes have now been linked to ALS, the exact pathogenic 
mechanisms are still largely unclear. Recent studies have suggested that both sporadic and familial 
forms of ALS share common pathologic mechanisms [38,39].  
3.1. Protein Misfolding and Aggregation 
Protein misfolding and aggregation are prominent features of ALS, but the relationship to disease 
pathogenesis remains unclear. A number of different protein inclusions are found in human ALS, and 
animal models of ALS, including ubiquitinated skein-like inclusions, bunina bodies, and hyaline 
inclusions rich in neurofilaments proteins [40]. Many proteins have been found within the inclusions in 
ALS, including neurofilaments proteins and peripherin [41], SOD1, p38MAPK and Cdf4 kinases [42], 
cystatin C [43], FUS [44] and TDP-43 [2]. SOD1 inclusions have been detected in lower motor 
neurons of familial ALS patients, mutant SOD1 transgenic mice, and in cultured cells expressing 
mutant SOD1 [45]. Wildtype SOD1 does not form large intracellular inclusions but may form smaller 
aggregates under oxidative stress [46]. It is unclear how protein aggregation is toxic to motor neurons, 
either by sequestration of proteins critical for cell viability, or by interfering with vital cellular 
mechanisms, such as chaperone activity, inhibiting the ubiquitin-proteasome system and disrupting of 
cellular transport [16]. 
3.2. Excitotoxicity 
Glutamate excitotoxicity results from the excessive influx of calcium cations through the   
over-stimulation of post-synaptic glutamate receptors, including NMDA and AMPA-type receptors [47]. 
This increase of calcium can activate enzymes such as phosphatases, proteases, lipases and 
endonucleases, causing protein and lipid alterations in cell membranes, generation of toxic reactive 
oxygen species (ROS), and mitochondrial damage and dysfunction [47]. Decreased levels of the 
excitatory amino acid transporter EAAT2, which is present on astrocytes and is responsible for rapid 
removal of glutamate from the synapse, are found in both human patients and in mutant SOD1 
transgenic rodents [48]. Furthermore, increased glutamate is found in CSF of ALS patients [49]. 
Riluzole, which is the only approved treatment for ALS at present, is thought to inhibit glutamate 
release from synapses [50]; however, riluzole only moderately improves survival in ALS patients [51]. 
Overexpressing EAAT2 in mutant SOD1 transgenic mice decreases excitotoxicity, delays disease Int. J. Mol. Sci. 2011, 12 9061 
 
 
onset, slows disease progression and prolongs life-span [52], but only partially increases 
neuroprotection [53]. Thus, exicitotoxicity may be involved in modulation of disease progression.  
3.3. Neuroinflammation 
Neuroinflammation is characterized in ALS by the appearance of reactive microglial and astroglial 
cells [5,6], suggesting a non-cell autonomous process [54]. In ALS, reactive astrocytes produce nitric 
oxide and peroxynitrite, and trigger mitochondrial damage and apoptosis in motor neurons [55]. 
Astrocytes may also contribute to excitotoxic damage to motor neurons as discussed above. 
Furthermore, microglial cells are reported to be activated in the brain and spinal cord of patients with 
ALS, as well as mutant SOD1 transgenic mice [56] and activated microglia were detected before 
motor neuron loss [56]. Damage within motor neurons is enhanced by injury from microglial cells via an 
inflammatory response that accelerates disease progression [57]. Furthermore, treatment of ALS with 
minocycline, a tetracycline derivative that inhibits microglial activation, increases survival and delays 
disease onset in SOD1
G93A transgenic mice [58]. Hence, understanding the cross-talk between motor 
neurons and their non-neuronal neighbours may lead to understanding how these factors act in concert 
to drive disease progression. 
3.4. Mitochondrial Disturbances and Oxidative Stress 
Changes in mitochondrial structure and function, and activation of mitochondrial dependent 
apoptosis, have been described in animal and cellular models of ALS, as well as in patients with  
ALS [59,60]. In SOD1
G93A transgenic mice, mitochondrial degeneration and vacuolation are reported 
very early, at 2 weeks of age [8,61], suggesting that mitochondrial abnormalities are an early event in 
disease pathogenesis. Furthermore, mutant SOD1 associates with mitochondrial compartment, such as 
intermembrane space of mitochondria, from where it may trigger apoptosis [62]. Mitochondrial-dependent 
apoptosis, including redistribution of cytochrome c from mitochondria to cytosol and recruitment of 
proapoptotic Bax to mitochondria are associated with mutant SOD1 inclusion formation [60]. 
Dysfunction of components of the mitochondrial respiratory chain are also evident in the spinal cord of 
SOD1
G93A transgenic mice at disease end stage [63]. Expression of mutant SOD1 in cell culture 
induces a significant loss of mitochondrial membrane potential and increases mitochondrial ROS 
production, suggesting that respiratory chain dysfunction and mitochondrial depolarization are 
underway [7]. Impaired axonal transport of mitochondria has been reported in ALS [64], although a 
recent study demonstrates that impairment of mitochondrial transport in SOD1
G93A transgenic mice 
plays a minimal role in ALS pathology [65]. Furthermore, mutant SOD1 targeting to the mitochondria 
impaires mitochondrial dynamics and also is associated with impaired maintenance of neuritic 
processes [66]. Axonal transport of mitochondria may be essential to neurons due to their extensive 
processes between the cell body and the synapse at the cell periphery [67]. 
3.5. ER Stress 
We and other groups have demonstrated that ER stress is an important pathway to cell death in  
ALS [68,69], and is triggered very early in SOD1
G93A transgenic mice at p5 [70]. ER stress is triggered Int. J. Mol. Sci. 2011, 12 9062 
 
 
when misfolded proteins accumulate within the ER lumen, inducing the unfolded protein response 
(UPR). Although the initial phases of the UPR aim to promote cell survival, prolonged or severe ER 
stress triggers the apoptotic phase of the UPR. Upregulation of the three UPR sensor proteins, PERK, 
ATF6 and IRE1, have been observed both at the symptom onset and at disease end stage of SOD1
G93A 
transgenic mice, implying the involvement of ER stress in disease mechanisms [68,71]. The ER 
chaperone, protein disulphide isomerase (PDI), was found to co-localize with mutant SOD1 inclusions 
in both cellular and animal models of ALS [72] and overexpression of PDI decreased mutant SOD1 
aggregation, ER stress, and apoptosis [72]. However, it remains unclear how ER stress is triggered in 
ALS because SOD1 and the other proteins linked to ALS are not associated with the ER. 
4. Axonal Transport in Neurons 
The major roles of axonal transport are to move newly synthesized proteins or lipids to the distal 
axon or synapse to maintain axonal and synaptic activity, and to clear proteins and organelles from the 
axon or synapse to the cell soma for efficient degradation. Axonal transport also plays a role in the 
communication of intracellular signals from the distal axon to the soma, allowing the neuron to 
respond to changes in the environment. Another important function is the transport of mitochondria to 
provide energy in the axon or synapse. Defects in either supply or clearance of material within an axon 
can lead to neuronal death.  
Molecular motors from the kinesin, dynein, and myosin super-families transport cargo within 
neurons and other cell types [73,74]. Both microtubules and neurofilaments are the major longitudinal 
cytoskeletal filaments within the axon and dendrites and the molecular motors move along 
microtubules during transport. In the synaptic regions, such as pre-synaptic terminals and post-synaptic 
spines, actin filaments form the main cytoskeletal architecture [75], and myosins are the main 
molecular motor which conveys cargos along actin filaments [76]. Axonal transport occurs   
bi-directionally, from the cell body to the periphery (anterograde transport) and from the periphery to 
the cell body (retrograde transport). The direction of transport depends on the polarity of the rails. In 
the axon, microtubules have unipolar orientation: the fast growing “plus” end points towards the 
synapse, and the “minus” end points towards the soma [77]. However, in the dendrites, the microtubule 
polarity is mixed. Actin filaments also have polarity: the barbed end (the growing end) points to the 
plasma membrane in pre-synaptic and post-synaptic regions.  
Classically and functionally, axonal transport is divided into fast and slow axonal transport based on 
the bulk speed of cargo movement. Vesicles and mitochondria move by fast axonal transport at speeds of 
~1 µm/s, whereas cargoes such as cytoskeleton components move slowly at speeds of ~1 mm/day [78]. 
Movement is also intermittent in slow axonal transport with individual cargoes pausing during their 
transit within the axon [15,79]. 
5. Molecular Motor Proteins: Kinesin, Dynein, Myosin 
Kinesin superfamily proteins (KIFs) are composed of a motor domain, a stalk domain and a   
tail region [80]. The conserved globular motor domain consists of an ATP-binding site and a 
microtubule-binding sequence. The motor domain hydrolyzes ATP and transfers chemical energy for 
the movement of each KIF along microtubules with intrinsic directionality. The tail regions and the Int. J. Mol. Sci. 2011, 12 9063 
 
 
filamentous stalk regions recognize and bind to the cargo(s) [81]. While motor domains show high 
amino acid sequence homologies (30–60%) among the KIFs, the other regions exhibit significant 
variability [82,83].  
KIFs can be broadly grouped into three types depending on the position of the motor domain within 
the molecule. The motor domain is found in the NH2-terminal region in N-kinesins, in the middle of 
the protein in M-kinesins, and at the COOH terminus in the C-kinesins. N-kinesins generally move 
toward microtubule plus ends, while C-kinesins move toward minus ends, and M-kinesins depolymerise 
microtubules [84,85]. The kinesin superfamily comprises at least 45 members in mammals such   
as human and mouse [86] and the KIFs are classified into 14 families based on head domain   
homology [86–89]. These include one M-kinesin family, one C-kinesin family, and 12 N-kinesin 
families. KIFs usually drive anterograde transport while most retrograde transport is mediated by 
cytoplasmic dynein, although a few kinesins also power retrograde transport [90–92]. 
In striking contrast to the kinesin family with its diverse members, cytoplasmic dynein utilizes its 
single structural form to carry out a wide variety of cellular functions, many of which are similar  
to those produced by the kinesins. Dyneins are members of the AAA+ superfamily (AAA),   
ATPase-associated proteins with various cellular activities [93]. Dynein motor proteins couple ATP 
hydrolysis to movement along microtubules towards the minus end and they can carry a large variety 
of cargoes. Dynein superfamily proteins comprise two major groups, cytoplasmic dynein and 
axonemal dyneins, which are also called ciliary or flagellar dyneins. The complete dynein motor is a 
large, multi-protein complex (1.5 MDa) composed of two identical heavy chains, two intermediate 
chains, four light intermediate chains and several light chains. Cytoplasmic dynein has an important 
associated protein complex called dynactin, containing p150
Glued, p62, dynamitin, actin related protein 
(Arp) 1, CAPZα and CAPZβ, p27, and p24. Dynactin regulates dynein activity and the binding 
capacity of dynein for its cargos [94]. The homodimer heavy chain of dynein binds to microtubules 
and enables dynein to move in an ATP-dependent manner [95]. The other subunits of dynein are 
thought to maintain the stability of the complex, to modulate its activity and to interact with accessory 
and cargo proteins [96–98]. Cytoplasmic dynein may also perform tasks other than the transport of 
cargos; for example, endosomes depend on dynein not just for their motility, but also for their 
maturation, morphology and receptor sorting [99].  
Dynein and kinesins function in an inter-dependent manner, and the disruption of movement in one 
direction can also affect movement in the opposite direction [100]. The intermediate chain of dynein 
can bind directly to kinesin light chains 1 and 2 [101], and dynactin is able to interact not only with 
dynein but also with several kinesins [102]. Hence, the regulation of axonal transport processes 
extremely complex. 
Myosin superfamily motor proteins bind to actin and hydrolyse ATP to generate force and 
movement along actin filaments. They are classified into 18 classes, mostly based on comparisons and 
phylogenetic analysis of the conserved motor domain [103]. They play significant roles in cell 
movement, muscle contraction, cytokinesis, membrane trafficking, and signal transduction. Most 
myosins form a dimer and consist of a motor domain, a neck region, and a tail region. Int. J. Mol. Sci. 2011, 12 9064 
 
 
6. Molecular Motors in SOD1-Associated ALS 
There is increasing evidence for dysfunction of axonal transport in the pathogenesis of ALS. In 
SOD1
G93A transgenic mice, defects in both anterograde and retrograde axonal transport are   
observed [104]. There is also evidence that impairment of axonal retrograde transport is one of the 
earliest axonal pathologies in SOD1
G93A transgenic mice, suggesting deficits in axonal transport are a 
key pathogenic event in ALS [10]. Both fast and slow axonal transport were also impaired in the 
ventral roots of transgenic mice with low copy number of mutant SOD1 [105]. Swollen axon segments 
or spheroids are also present in spinal cords of human ALS and SOD1
G93A transgenic mice [106]. Also, 
axonal disorganization and the accumulation of neurofilament proteins are hallmarks of both sporadic 
and inherited forms of ALS [107–109]. Mice overexpressing human neurofilament heavy-subunit gene 
(NF-H) posses dramatic defects in axonal transport, not only of neurofilament proteins but also of 
other proteins, including tubulin and actin [107]. Point mutation of the p150 subunit of dynactin has 
been detected in both sporadic and familial ALS patients [110]. Mutations in dynactin lead to a 
reduction in retrograde transport but disease progression is less severe than ALS in transgenic   
mice [31]. In contrast, mutations in cytoplasmic dynein can either result in pure sensory neuropathy or 
in a sensory neuropathy with motor neuron involvement [111]. A recent study suggested that 
alterations in retrograde signalling contribute to neurodegeneration in ALS, by shifting from the 
transport of survival-promoting to death-promoting signalling cargo molecules [112]. Mutant SOD1 
also inhibits anterograde fast axonal transport of mitochondria enhances the retrograde movement 
resulting in a depletion of axonal mitochondria content [113]. Mislocalization of mutant SOD1 is 
observed in axonal mitochondria within motor neurons, accompanied by intra-axonal accumulation of 
misfolded SOD1 [114]. Considering the very long axon of the motor neuron and the relative 
abundance of mitochondria within these axons, mitochondrial transport disturbances are expected to 
have a significant impact on the overall function of the motor neuron [114]. Evidence suggests that 
axonal transport alterations are an early event in ALS, thus implicating axonal transport in the 
pathogenesis of ALS. 
6.1. Kinesins 
Kinesins mediate anterograde axonal transport, which is essential for synapse generation and for 
maintaining synaptic transmission [80]. Several studies have highlighted the importance of kinesin in 
ALS, particularly kinesin heavy chain genes, KIF5A and KIF1Bβ, which transport mitochondria, 
synaptic vesicles and macromolecular complexes. A recent study demonstrated that oxidized wildtype 
SOD1, and wildtype SOD1 immunopurified from sporadic ALS patient tissues, inhibited kinesin-
based fast axonal transport in a manner similar to mutant SOD1 in familial ALS, suggesting common 
pathogenic mechanisms in both sporadic and familial ALS [38]. Disruption of KIF5A in neurons 
postnatally does not affect fast axonal transport; however, it induces a reduction in slow anterograde 
axonal transport, resulting in an accumulation of neurofilament proteins in the cell bodies of peripheral 
sensory neurons and a reduction in sensory axon calibre [115]. Similarly, the expression of KIF1Bβ 
mutants in mice induces defects in the anterograde transport of synaptic vesicle precursors, resulting in 
a late-onset axonopathy [116]. These pathological effects closely mimic those observed in individuals Int. J. Mol. Sci. 2011, 12 9065 
 
 
bearing mutations in the KIF5A and KIF1Bβ genes, which have been identified in families with 
hereditary spastic paraplegia [117] and Charcot-Marie Tooth type 2A neuropathy [116]. Furthermore, 
not only mutations, but lower expression of KIF has been associated with neurodegeneration. For 
example, reduction in the levels of kinesin associated protein 3 (KIFAP3) has been linked to increased 
survival in ALS patients [118], which may be due to changes in axonal transport of choline 
acetyltransferase (ChAT) [119]. Hence, KIFAP3 can be considered as a potential modifier of the ALS 
phenotype [120]. KIFAP3 is part of the trimeric motor kinesin II complex (KIF3) that is involved in 
multiple functions including intracellular transport [121]. Furthermore, a specific downregulation of  
kinesin-related proteins, KIF1Bβ and KIF3Aβ, has been detected in motor cortex specimens of 
sporadic ALS patients [122]. Nevertheless, interaction between mutant SOD1 and members of the 
kinesin-1 family (KIF5A, 5B, or 5C) was not observed in spinal cords of SOD1
G93A transgenic mice at 
60 days of age, suggesting that impairment of anterograde transport occurs on the verge of developing 
clinical symptoms [123]. In comparison to dynein, relatively few degenerative diseases have been 
directly linked to kinesin, possibly due to functional redundancy in the large kinesin superfamily.  
6.2. Dyneins 
Dynein is very highly expressed in neurons [124] and neurons are particularly sensitive to defects in 
dynein/dynactin function [78]. A dynein subunit was identified as a component of mutant   
SOD1-containing high molecular weight complexes prior to the onset of symptoms in ALS animal 
models and increased during disease progression [125]. Furthermore, mutations in the dynactin 1 gene 
(DCTN1), encoding the p150Glued subunit of dynactin, cause human distal hereditary   
motor neuropathy (HMN7B) [31,126]. Knock-in and transgenic mice expressing these mutations 
subsequently develop motor neuron degeneration [127,128]. Over-expression of the dynactin subunit 
dynamitin in mice leads to impairment of dynein-dynactin interaction and a late-onset progressive 
disease reminiscent of ALS [129]. Mutation of the dynein heavy chain 1 gene causes motor neuron 
degeneration and inhibition of axonal transport [130]. Loa (legs at odd angles) and Cra1 (Cramping1) 
mice which carry separate N-ethyl-N-nitrosourea-induced mutations of the dynein heavy chain 1 gene, 
show selective impairment of axonal retrograde transport as well as progressive locomotor disorders 
associated with spinal motor neuron degeneration [130]. Also, a third mouse model (Swl) with another 
dynein heavy chain gene mutation displays an early-onset sensory neuropathy with muscle spindle 
deficiency [131]. Hence, the relative contributions of sensory and motor neuron degeneration to the 
phenotypes of Loa, Cra1, and Swl mice are still under debate. 
Surprisingly, crossing the SOD1
G93A transgenic mouse with Loa or Cra1 animals delays disease 
progression and significantly increases lifespan [132]. This amelioration correlates with a complete 
recovery of the axonal transport deficits in motor neurons of these mice [132,133]. However, this 
observation was partially explained recently by a proteomics study which revealed that the SOD1 
mutation augments retrograde transport of stress factors (p-JNK, caspase-8 and p75NTR cleavage 
fragment) and simultaneously impairs retrograde transport of survival factors (p-Trk and p-Erk1/2) [134]. 
Dynein also plays a role in the transport of nerve injury signals, phosphorylated Erk [135], and 
phosphorylated JNK [136]. Many types of protein cargoes transported by dynein are implicated in 
ALS [134]. Impaired retrograde transport of activated neurotrophin receptors by direct association of Int. J. Mol. Sci. 2011, 12 9066 
 
 
the dynein light chain with Trk neurotrophin receptors may also trigger neurodegeneration [137,138]. 
Dynein is involved in the autophagic clearance of misfolded proteins [139] and removal of damaged 
organelles and proteins from the axonal compartment [140]. Therefore, clearance of misfolded proteins 
in ALS is affected by dysfunction of dynein.  
It is clear that dynein-mediated retrograde axonal transport is affected in motor neurons in ALS [123]; 
however, the underlying mechanisms are still unclear. Mutations in the dynein-dynactin machinery 
cause phenotypes that may influence multiple processes including neurotrophic factor delivery, 
transport, and homeostasis of mitochondria and protein aggregation or degradation. Disruption of 
dynein function could therefore link several proposed pathways relevant to ALS pathophysiology, 
including axonal transport, mitochondrial dysfunction, and mutant SOD1 aggregation. 
7. Dynein-Mediated ER-Golgi Transport in ALS 
The transport of secretory proteins between the ER and Golgi apparatus is also dynein mediated, 
and dysfunction of the ER-Golgi is also implicated in diseases of motor neurons, suggesting a link 
between ER-Golgi and axonal transport processes [129]. Also, dynein dysfunction can result in 
fragmentation of the Golgi apparatus [141], which occurs in spinal and cortical motor neurons in ALS 
patients, in cell lines over-expressing mutant SOD1 [142], and is also one of the first pathological 
events in SOD1
G93A transgenic mice [143].  
The ER and Golgi apparatus regulate protein trafficking and secretion. The ER is responsible for the 
sorting, post-translational modification and trafficking of transmembrane and secretory proteins [144,145]. 
Vesicles containing secretory protein cargo bud from the ER, fuse with the cis-Golgi network and 
subsequently progress to the trans-Golgi network, from where they are transported to further cell was 
locations. Approximately a third of all cellular proteins are secreted via this classical ER-Golgi pathway. 
Hence, inhibition of ER-Golgi function and transport could severely impact on cellular function. The 
relationship between dynein-mediated ER-Golgi transport and axonal transport mechanisms is poorly 
understood, but the two processes are clearly linked (recently reviewed in [146]). 
7.1. ER-Golgi and Diseases of Motor Neurons 
Protein folding in the ER is required to maintain cellular function. Protein misfolding within the ER 
induces ER stress, triggering the UPR. The UPR mechanisms aim to restore homeostasis, but if 
homeostasis is not restored, cell death is triggered via apoptosis [147]. Cellular insults which lead to 
increased protein misfolding in the ER include changes in intracellular calcium concentration, 
alterations in the redox state of the ER, nutrient deprivation, failure of post-translational modifications 
and increases in secretory protein synthesis [148]. ER stress also induces ER-associated degradation 
(ERAD), a process by which proteins are removed from the ER and retrotranslocated to the cytosol, 
where they are degraded by the 26S proteasome. It has been reported that UPR induction is due to the 
interaction of cytoplasmic mutant SOD1 with Derlin-1, a key protein involved in ERAD [149], but this 
interaction was only detected after the onset of symptoms in transgenic SOD1 mice, suggesting that 
this mechanism is not the primary trigger of ER stress. However, it is now recognised that other 
cellular processes can cause secondary ER stress, such as disturbances of the ER, Golgi, endosomal 
and vesicular transport systems [150–152]. Int. J. Mol. Sci. 2011, 12 9067 
 
 
ER stress has been reported as a key role in mutant SOD1-linked ALS pathogenesis; however, the 
exact mechanisms that trigger ER stress in ALS remain elusive. Recent evidence also implicates the 
ER-Golgi in disease induced by TDP-43 and FUS in ALS. Recently, TDP-43 was detected in the 
rough ER in spinal cord motor neurons of sporadic ALS patients [153], suggesting that TDP-43 could 
be redistributed to the ER in disease. Furthermore, TDP-43 has been detected in mouse brainstem 
microsomes which contain ER and other vesicles [154], and pharmacological induction of ER stress 
increases the accumulation of TDP-43 in cell culture [155]. Similarly, FUS has also been linked to the 
ER: electron microscopy of spinal motor neurons of patients with juvenile ALS demonstrated   
FUS-positive inclusions associated with disorganised rough ER [156]. A key UPR protein, BiP, is also 
found in FUS-immunoreactive inclusions in ALS patient tissue, providing further evidence that ER 
stress could be involved in mutant FUS-linked ALS [157].  
7.2. ER-Golgi Vesicle Trafficking Defects 
Vesicle trafficking defects have been linked to human motor neuron diseases [158]. Dynamin 2, a 
vesicular traffic regulator modulates the actin cytoskeleton, interacts with actin-binding proteins such 
as profilin and Abp1 [159] and is involved in the fusion and fission of vesicles and other membranous 
organelles [160]. Atlastin 1 (SPG3A) and REEP1 mutations (SPG31) also result in marked ER 
morphological defects and altered synaptic vesicle recycling. Several familial forms of ALS are also 
linked to genes encoding proteins involved in the regulation and control of vesicle transport: VAPB, 
VCP and ALS2 [34,161,162]. Mouse mutants with motor phenotypes have been linked to defects in 
intracellular trafficking, such as the progressive motor neuronopathy (pmn) mouse, which accumulates 
the mutant tubulin-specific chaperone TBCE in the cis-Golgi compartment [163]. Also, the wobbler 
mouse, which displays motor neuron dysfunction, contains mutations in vacuolar-vesicular protein 
sorting factor Vps54, which is involved in Golgi-associated vesicular trafficking [164]. 
(a) Vesicle-associated membrane protein-associated protein B (VAPB) 
Missense mutations of VAPB, a widely expressed ER transmembrane protein [165], cause 
autosomal dominant typical ALS, slowly progressing atypical ALS or late-onset spinal muscular 
atrophy (SMA). VAPB is a highly conserved protein, which is localized in the ER and associated with 
microtubules [166]. VAPB has important function in ER and Golgi maintenance and neuronal 
transmission [165,167,168]. It is also involved in the regulation of ER−Golgi vesicle transport [169] 
and in modulating ER stress [170]. The two VAPB mutations described in ALS, P56S and T46I, 
perturb ER and Golgi trafficking [171] and cause morphological disruption to the ER [168,172,173]. 
These mutations also appear to increase motor neuron vulnerability to ER stress-induced death, by 
sequestering wild-type VAPB [174]. Mutant VAPB also induces the co-aggregation of wild-type 
VAPB [170,173], suggesting a dominant-negative mode of pathogenesis. Mutant P56S VAPB 
inclusions are ER derived [165,168], and co-locate with a subset of ER proteins [172]. VAPB proteins 
are also involved in axonal guidance [175], which may lead to axonal dysfunctions and contribute to 




Optineurin is also one of the disease-causing genes in ALS although it was earlier reported to be a 
causative gene in primary open-angle glaucoma. Optineurin is a Golgi-localized protein [176,177]; 
however, mutations in optineurin induce the formation of cytoplasmic inclusions in both sporadic and 
SOD1 cases of ALS [33,35]. Several interacting partners of optineurin have been recently identified, 
including GTPase molecular Rab8 [178], myosin VI [179], and transferrin receptor [180]. The 
redistribution of optineurin from the Golgi apparatus to the cytoplasm leads to Golgi fragmentation [181]. 
Together these data indicate a possible role for optineurin in protein trafficking and axonal transport 
dysfunction [182]. 
(c) Valosin containing protein (VCP) 
Recently using exome sequencing, ALS-causative mutations in the gene encoding valosin 
containing protein (VCP/p97) were identified in familial ALS patients [34]. VCP is a hexameric type 
II ATPase of the AAA family, with many putative roles, including transcription, cell division, Golgi 
assembly, autophagy, and in particular, aiding proteasome function [183–186]. Knockdown of VCP in 
HeLa cells leads to an increase in ubiquitinated proteins derived from the ER [187], and reduced levels 
of cellular VCP induce ER stress, perhaps as a consequence of reduced ERAD and/or by disturbing the 
fusion of ER membranes [188]. Motor neurons of an ALS patient with a VCP mutation were recently 
found to contain TDP-43-positive inclusions [34], similar to VCP mutations linked to frontotemporal 
lobar dementia (FTLD) [189]. VCP mutations in FTLD were also found to induce ER stress and cell 
death in cell culture [189]. Interestingly, VCP is involved in ERAD by binding to the ER 
transmembrane protein Derlin-1 [190,191]. The association of Derlin-1 with activation of the UPR in 
mutant SOD1 cellular and mouse models of ALS [192] suggests overlap in the pathogenic disease 
mechanisms triggered by VCP, TDP-43 and SOD1 related to ER stress and ERAD. 
8. Do Mutant TDP-43 and Mutant FUS also Induce Molecular Motor Dysfunction? 
Most of the evidence demonstrating the involvement of molecular motor proteins in ALS comes 
from the study of SOD1 disease models. A role for the other major proteins recently linked to ALS, 
TDP-43 and FUS, in molecular motor dysfunction remains yet to be established. Translocation of both 
TDP-43 and FUS from the nucleus to cytoplasm induces the formation of inclusions and is linked to 
pathology [193–195]. Previous studies have shown that axonal ligation induces transient redistribution 
of TDP-43 to the cytoplasm and peripheral axonal accumulation of TDP-43 in brainstem motor 
neurons [154,193]. Moreover, nuclear-excluded TDP-43 co-localized with RNA transport markers and 
stress granules, indicating that TDP-43 plays a role in sequestering and regulating mRNA levels in 
response to axonal injury [154]. Both TDP-43 and FUS also play a role in mRNA transport to 
dendrites in an activity-dependent manner [196]. These data together suggest that accumulation of 
TDP-43 or FUS in the cytoplasm could lead to transport impairment and axonal injury. Due to the 
functional similarities between TDP-43 and FUS, the pathological mechanisms associated with these 




Motor neurons are highly polarized cells, and hence cellular transport is a fundamental process for 
the survival and maintenance of motor neurons. Increasing evidence implicates transport defects in the 
etiology of ALS. Studies using SOD1 transgenic mice clearly show that axonal transport impairment 
contributes to motor neuron degeneration. Moreover, mutations in genes encoding motor proteins 
provide direct evidence for a role in the pathogenesis of ALS. Although dysfunction of motor proteins 
in ALS directly triggers defects in transport, it is possible that other ALS-associated proteins are 
directly or indirectly linked to an impairment of transport. However, this requires further studies. 
Hence, identifying the common pathophysiological mechanisms in ALS is crucial. A powerful 
combination of genetic, cellular, and biochemical approaches have revealed new and often unexpected 
insights, and the further development of our understanding of molecular motors and their role in ALS 
will hopefully lead to the development of improved therapies for ALS. 
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